Flu and RSV are packing a post-holiday one-two punch, sending people into Erie's emergency departments and medical offices ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

The novel treatment consists of a single shot which is made of special proteins called antibodies that bind to the site at ...

We’re still in the early stages of RSV season, but doctors are already worried about a rise in cases. As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...